Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation

Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantationSafety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation, Published online: 26 April 2018; doi:10.1038/s41409-018-0182-9Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation

Source: Bone Marrow Transplantation - April 26, 2018 Category: Hematology Authors: Kyle R. Brownback Lucas R. Pitts Sunil Abhyankar Source Type: research